FDA Approves First Respiratory Syncytial Virus (RSV) Vaccine
FDA approved Arexvy, the first RSV vaccine approved for use in the U.S. Arexvy is approved for the prevention of lower respiratory tract disease caused by RSV.
www.fda.govHere’s the latest on RSV vaccinations.
-
Global and US regulatory progress: The first RSV vaccines for adults 60+ were approved in the US in 2023, with ongoing updates as more data emerge on broader age groups and pregnant individuals for maternal immunization. Additional ACIP recommendations and provider updates have continued to expand eligible groups, including high-risk adults starting around ages 50–59 in some guidance.[1][2][3]
-
Current recommended groups in many systems (US-focused):
- Adults aged 60+ (original approval group) and other high-risk adults.
- Pregnant individuals to protect newborns via maternal immunization.
- Some guidance now includes select adults aged 50–59 with underlying conditions, though final CDC/HHS confirmation may vary by season and program updates.[2][3][4]
-
Availability and access: RSV vaccines are offered at major pharmacies and healthcare providers; many systems advertise no-cost or low-cost vaccination options, especially for those eligible per state or payer guidelines.[3][5]
-
Seasonal and policy context: Health authorities in several countries (including the UK and US) have emphasized RSV vaccination as part of seasonal respiratory infection prevention, alongside influenza vaccination campaigns for the upcoming season.[6][3]
-
What to consider for timing and eligibility:
- If you’re pregnant or near the window for maternal immunization, vaccination during pregnancy can protect newborns in the first months of life.[6]
- If you’re 60+ or in a high-risk category, talk to your clinician about RSV vaccination as part of your preventive care.[1][2]
- For adults aged 50–59 with chronic conditions, check current ACIP/CDC updates or your local health department guidance, as recommendations have evolved and are season-dependent.[8][2]
Illustration: A simple snapshot of current eligibility shifts over time (older adults 60+, high-risk adults 50–59 in some updates, and maternal immunization) shows how recommendations expand as vaccine safety and effectiveness data accumulate.[2][1][6]
Would you like a brief country-specific update (US, UK, or Italy) with current vaccination eligibility and where to get the vaccine near you in Figino, Lombardy? I can pull the latest local guidance and vaccination sites if you want.[5][1][6]